The Research Progress of PD-1/PD-L1 Inhibitors Enhancing Radiotherapy Efficacy

被引：18

作者：

Wen, Lu ^{[1
]}

Tong, Fan ^{[1
]}

Zhang, Ruiguang ^{[1
]}

Chen, Lingjuan ^{[1
]}

Huang, Yu ^{[1
]}

Dong, Xiaorong ^{[1
]}

机构：

[1] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Ctr Canc, Wuhan, Peoples R China

来源：

FRONTIERS IN ONCOLOGY | 2021年 / 11卷

基金：

国家重点研发计划;

关键词：

radiotherapy; immunotherapy; PD-1; PD-L1; inhibitors; abscopal effect; STEREOTACTIC ABLATIVE RADIOTHERAPY; CD8(+) T-CELLS; FRACTIONATED RADIOTHERAPY; ANTITUMOR IMMUNITY; RADIATION-THERAPY; IMMUNOTHERAPY; IRRADIATION; BLOCKADE; RESISTANCE; RESPONSES;

D O I：

10.3389/fonc.2021.799957

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Approximately 60%-70% of patients with malignant tumours require radiotherapy. The clinical application of immune checkpoint inhibitors (ICIs), such as anti-PD-1/PD-L1, has revolutionized cancer treatment and greatly improved the outcome of a variety of cancers by boosting host immunity.However, radiotherapy is a double-edged sword for PD-1/PD-L immunotherapy. Research on how to improve radiotherapy efficacy using PD-1/PD-L1 inhibitor is gaining momentum. Various studies have reported the survival benefits of the combined application of radiotherapy and PD-1/PD-L1 inhibitor. To fully exerts the immune activation effect of radiotherapy, while avoiding the immunosuppressive effect of radiotherapy as much as possible, the dose selection, segmentation mode, treatment timing and the number of treatment sites of radiotherapy play a role. Therefore, we aim to review the effect of radiotherapy combined with anti-PD-1/PD-L1 on the immune system and its optimization.

引用

页数：8

共 78 条

[1] Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Kurata, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

Carpeno, J. de Castro ;

Faivre-Finn, C. ;

Reck, M. ;

Vansteenkiste, J. ;

Spigel, D. R. ;

Wadsworth, C. ;

Melillo, G. ;

Taboada, M. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24) :2342-2350

[2] Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial [J].

Ball, David ;

Mai, G. Tao ;

Vinod, Shalini ;

Babington, Scott ;

Ruben, Jeremy ;

Kron, Tomas ;

Chesson, Brent ;

Herschtal, Alan ;

Vanevski, Marijana ;

Rezo, Angela ;

Elder, Christine ;

Skala, Marketa ;

Wirth, Andrew ;

Wheeler, Greg ;

Lim, Adeline ;

Shaw, Mark ;

Schofield, Penelope ;

Irving, Louis ;

Solomon, Benjamin .

LANCET ONCOLOGY, 2019, 20 (04) :494-503

[3] Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort [J].

Barata, Pedro ;

Hatton, Whitley ;

Desai, Arpita ;

Koshkin, Vadim ;

Jaeger, Ellen ;

Manogue, Charlotte ;

Cotogno, Patrick ;

Light, Malcolm ;

Lewis, Brian ;

Layton, Jodi ;

Sartor, Oliver ;

Basu, Arnab ;

Kilari, Deepak ;

Emamekhoo, Hamid ;

Bilen, Mehmet A. .

FRONTIERS IN ONCOLOGY, 2020, 10

[4] Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma [J].

Barsoumian, Hampartsoum B. ;

Ramapriyan, Rishab ;

Younes, Ahmed, I ;

Caetano, Mauricio S. ;

Menon, Hari ;

Comeaux, Nathan, I ;

Cushman, Taylor R. ;

Schoenhals, Jonathan E. ;

Cadena, Alexandra P. ;

Reilly, Timothy P. ;

Chen, Dawei ;

Masrorpour, Fatemeh ;

Li, Ailin ;

Hong, David S. ;

Diab, Adi ;

Nguyen, Quynh-Nhu ;

Glitza, Isabella ;

Ferrarotto, Renata ;

Chun, Stephen G. ;

Cortez, Maria Angelica ;

Welsh, James .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)

[5] Local Recurrence Outcomes of Colorectal Cancer Oligometastases Treated With Stereotactic Ablative Radiotherapy [J].

Benson, Kathryn R. K. ;

Sandhu, Navjot ;

Zhang, Carrie ;

Ko, Ryan ;

Toesca, Diego A. S. ;

Lee, Phoebe E. ;

Von Eyben, Rie ;

Diehn, Maximilian ;

Gensheimer, Michael ;

Maxim, Peter G. ;

Bush, Karl ;

Loo, Billy W., Jr. ;

Soltys, Scott G. ;

Pollom, Erqi L. ;

Chang, Daniel T. .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2021, 44 (11) :559-564

[6] Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? [J].

Bernstein, Michael B. ;

Krishnan, Sunil ;

Hodge, James W. ;

Chang, Joe Y. .

NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (08) :516-524

[7] Time to abandon single-site irradiation for inducing abscopal effects [J].

Brooks, Eric D. ;

Chang, Joe Y. .

NATURE REVIEWS CLINICAL ONCOLOGY, 2019, 16 (02) :123-135

[8] STAT3 Induces Immunosuppression by Upregulating PD-1/PD-L1 in HNSCC [J].

Bu, L. L. ;

Yu, G. T. ;

Wu, L. ;

Mao, L. ;

Deng, W. W. ;

Liu, J. F. ;

Kulkarni, A. B. ;

Zhang, W. F. ;

Zhang, L. ;

Sun, Z. J. .

JOURNAL OF DENTAL RESEARCH, 2017, 96 (09) :1027-1034

[9] Systemic Analysis and Review of Nivolumab-ipilimumab Combination as a Rescue Strategy for Renal Cell Carcinoma After Treatment With AntiePD-1/PD-L1 Therapy [J].

Carril-Ajuria, Lucia ;

Lora, David ;

Carretero-Gonzalez, Alberto ;

Martin-Soberon, Maricruz ;

Rioja-Viera, Patricia ;

Castellano, Daniel ;

de Velasco, Guillermo .

CLINICAL GENITOURINARY CANCER, 2021, 19 (02) :95-102

[10] Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy [J].

Chakraborty, M ;

Abrams, SI ;

Camphausen, K ;

Liu, KB ;

Scott, T ;

Coleman, CN ;

Hodge, JW .

JOURNAL OF IMMUNOLOGY, 2003, 170 (12) :6338-6347

← 1 2 3 4 5 6 7 8 →